ReviewInternational journal of molecular medicine2026
ETS‑1/ETS‑2 transcription factors in CVD (Review).
Review in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases remain the leading cause of global morbidity and mortality, imposing a significant burden on families and societies. E26 transformation‑specific (ETS)‑1 and ETS‑2, members of the ETS family of transcription factors (also known as proto‑oncogenes), are increasingly recognized for their roles in tumor progression. Recent studies highlight their importance in normal coronary artery development, myocardial homeostasis and the regulation of vascular inflammation and remodeling. Emerging evidence suggests that ETS‑1/ETS‑2 are critical in the pathogenesis of atherosclerosis, myocardial ischemia‑reperfusion injury, cardiac remodeling and heart failure. The present review summarized the research progress of ETS‑1/ETS‑2 in cardiovascular diseases, discusses the relevant challenges encountered in the translational process of ETS‑1/ETS‑2‑targeted therapy for cardiovascular diseases and provides novel strategies for the treatment of cardiovascular diseases targeting ETS‑1/ETS‑2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.